Invention Grant
- Patent Title: Antisense compounds targeting apolipoprotein E receptor 2
-
Application No.: US15315828Application Date: 2015-06-04
-
Publication No.: US10472634B2Publication Date: 2019-11-12
- Inventor: Frank Rigo , Michelle L. Hastings
- Applicant: Ionis Pharmaceuticals, Inc. , Rosalind Franklin University of Medicine and Science
- Applicant Address: US CA Carlsbad US IL North Chicago
- Assignee: Ionis Pharmaceuticals, Inc.,Rosalind Franklin University of Medicine and Science
- Current Assignee: Ionis Pharmaceuticals, Inc.,Rosalind Franklin University of Medicine and Science
- Current Assignee Address: US CA Carlsbad US IL North Chicago
- Agency: McNeill Baur PLLC
- International Application: PCT/US2015/034264 WO 20150604
- International Announcement: WO2015/187989 WO 20151210
- Main IPC: C12N15/113
- IPC: C12N15/113 ; C12N5/00

Abstract:
The present invention provides compounds comprising oligonucleotides complementary to an LRP8 transcript. Certain such compounds are useful for hybridizing to an LRP8 transcript, including but not limited, to an LRP8 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRP8 transcript. In certain embodiments, such hybridization results in an increase in inclusion of exon 19 in the LRP8 mRNA transcript. In certain embodiments, such compounds are used to treat Alzheimer's Disease.
Public/Granted literature
- US20170191066A1 ANTISENSE COMPOUNDS TARGETING APOLIPOPROTEIN E RECEPTOR 2 Public/Granted day:2017-07-06
Information query
IPC分类: